Breaking News

AAIPharma Expands Parenteral Manufacturing Facility

December 20, 2012

Adds formulation development capabilities

AAIPharma Services Corp. is expanding capacity and capabilities at its parenteral manufacturing facility in Charleston, SC. Facility expansions currently underway include the installation of compounding and aseptic processing suites to contain a newly acquired Monoblock vial filling machine, expansion of the microbiology lab, and addition of on-site formulation development capabilities and enhanced analytical instrumentation.
 
The fill and finish capabilities at the FDA- and EU-approved facility support vial sizes from 2 mL to 50 mL and can include 100% weight check. Manufactured products include solutions, lyophilized products, emulsions and suspensions with batch sizes ranging from a few hundred vials to 20,000 or more.
 
"In addition to the new fill line, integration of our formulation development and technical services capabilities through the build-out of a new pilot suite allows us to seamlessly support the manufacturing process from development through scale-up, further enhancing our compound to clinic strategy" said Paul Maffuid, Ph.D., vice president of pharmaceutical operations. "Expansion of the existing laboratories with a new cleanroom for on-site sterility testing using isolator technology continues our primary objective of providing a world-class parenteral manufacturing facility with all supporting infrastructure under one roof."
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO